Although HSP90 inhibitors have been intensively used in preclinical and clinical studies against PCa, whether noncoding RNAs regulate the activity of HSP90 in PCa cells and what the underlying mechanisms may be remain to be elucidated. This evidence concerns the gene HSP90AA1 and posterior cortical atrophy.